---
title: "ChengDa Pharmaceuticals' Facility Passes US FDA cGMP Inspection"
date: "2025-02-11 13:30:17"
summary: "ChengDa Pharmaceuticals successfully passed a US FDA on-site cGMP (current good manufacturing practice) inspection conducted from Nov. 11, 2024 to Nov. 15, 2024, according to a Monday filing with the Shenzhen Bourse. The inspection covered key areas such as quality systems, production, and laboratory controls at its Jiaxing, Zhejiang facility,..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

ChengDa Pharmaceuticals successfully passed a US FDA on-site cGMP (current good manufacturing practice) inspection conducted from Nov. 11, 2024 to Nov. 15, 2024, according to a Monday filing with the Shenzhen Bourse.

The inspection covered key areas such as quality systems, production, and laboratory controls at its Jiaxing, Zhejiang facility, focusing on manufacturing levocarnitine.

The FDA issued an Establishment Inspection Report (EIR) with a No Action Indicated (NAI) result, confirming compliance.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250211:G2466050:0/)
